Physical Therapists in Owings Mills, MD Accepting Medicare
84 Physical Therapists found. Showing 81 - 84
 Lee Miller Rehabilitation Associates Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 20 Crossroads Dr Ste 13, Owings Mills, MD 21117 Phone: 410-363-0015 Fax: 410-356-7763 |
 Mr. Francis Agustin Malcampo, RPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4730 Atrium Ct, Owings Mills, MD 21117 Phone: 410-998-8818 Fax: 410-363-8795 |
 Susan Bloom Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 20 Crossroads Dr Ste 13, Owings Mills, MD 21117 Phone: 410-363-0015 Fax: 410-356-7763 |
Dr. Kathryn Taylor Ogle, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 10084 Reisterstown Rd, Owings Mills, MD 21117 Phone: 443-394-2680 |
News Archive
nContact Surgical removes 'Surgical' from company name
nContact Surgical, Inc., a cardiac ablation device manufacturer, announced today that it is changing the name under which it operates from nContact Surgical, Inc. to nContact, Inc. As the pioneer of interdisciplinary epicardial and endocardial cardiac ablation, the change represents the Company's further evolution towards closed chest approaches to treating common cardiac arrhythmias.
Neuronal reprogramming may help treat neurodegenerative diseases
A new finding by Harvard stem cell biologists turns one of the basics of neurobiology on its head - demonstrating that it is possible to turn one type of already differentiated neuron into another within the brain.
USPTO confirms validity of DUSA's key Levulan PDT patent
DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."
Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.
› Verified 6 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Optometrists
Podiatrists
Chiropractors
Audiologists